After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

Q4 2025 Press Conference Call March 5, 2026 4:00 AM ESTCompany ParticipantsAxel LoberBelén Garijo López - Chair of Executive Board ...

Merck KGaA (ETR:MRK) executives told investors the company delivered “solid” organic growth in 2025 despite a challenging ...

Investing.com -- Merck KGaA (ETR:MRCG) on Thursday warned adjusted operating profit margins would shrink in 2026 as patent ...

Merck KGaA expects its 2026 adjusted operating profit to decrease by up to 4%, excluding currency effects, according to its latest statement.

Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple ...

Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as ​9.8%, hurt by negative currency effects and the loss of ​patent protection for a multiple sclerosis drug.

In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on ...

Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value CatalystsMarket News Updates News ...

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across ...

NORD Calls on Nation to "Show Your Stripes®" on Global Rare Disease Day®, Feb. 28NORWELL, Mass., Feb. 23, 2026 /PRNewswire/ - ...

Find insight on Merck KGaA and Granules India in the latest Market Talks covering the health care sector.